NEW YORK—Bayer AG plans to spend $1 billion on drug research and development in the U.S. this year as it works to double its sales in the country by the end of the decade, Bayer’s top U.S. pharmaceutical executive told Reuters.
Sebastian Guth, president of Bayer’s pharmaceuticals business in the Americas, also said in an interview on Wednesday that the company had raised the number of U.S. employees working on marketing for its pharmaceutical business by around 50 percent over the last three years, and plans to expand on that by another 75 percent by 2030.
